These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21787192)

  • 1. Pharmacogenomics of cisplatin-induced ototoxicity.
    Mukherjea D; Rybak LP
    Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
    Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
    Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in interpreting the evidence for genetic predictors of ototoxicity.
    Ratain MJ; Cox NJ; Henderson TO
    Clin Pharmacol Ther; 2013 Dec; 94(6):631-5. PubMed ID: 24241639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
    Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
    J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
    Hagleitner MM; Coenen MJ; Patino-Garcia A; de Bont ES; Gonzalez-Neira A; Vos HI; van Leeuwen FN; Gelderblom H; Hoogerbrugge PM; Guchelaar HJ; Te Loo MW
    PLoS One; 2014; 9(12):e115869. PubMed ID: 25551397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
    Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
    Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
    Mironovich OL; Bliznetz EA; Garbaruk ES; Belogurova MB; Subora NV; Varfolomeeva SR; Kachanov DY; Shamanskaya TV; Markova TG; Polyakov AV
    Vestn Otorinolaringol; 2018; 83(4):60-66. PubMed ID: 30113582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic markers of cisplatin-induced hearing loss in children.
    Carleton BC; Ross CJ; Pussegoda K; Bhavsar AP; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
    Clin Pharmacol Ther; 2014 Sep; 96(3):296-8. PubMed ID: 25141953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
    Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
    Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
    Carleton BC; Ross CJ; Bhavsar AP; Amstutz U; Pussegoda K; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
    Clin Pharmacol Ther; 2014 Mar; 95(3):253. PubMed ID: 24193170
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
    Lanvers-Kaminsky C; Ciarimboli G
    Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic background of cisplatin induced ototoxicity].
    Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
    Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.
    Lanvers-Kaminsky C; Malath I; Deuster D; Ciarimboli G; Boos J; Am Zehnhoff-Dinnesen AG
    Clin Pharmacol Ther; 2014 Aug; 96(2):156-7. PubMed ID: 24642735
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
    Carleton BC; Ross CJ; Bhavsar AP; Lee JW; Visscher H; Rassekh SR; Hayden MR
    Clin Pharmacol Ther; 2014 Aug; 96(2):158. PubMed ID: 24755913
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetics of cisplatin ototoxicity: confirming the unexplained?
    Boddy AV
    Clin Pharmacol Ther; 2013 Aug; 94(2):198-200. PubMed ID: 23872836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
    Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
    Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
    Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
    Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
    Yang JJ; Lim JY; Huang J; Bass J; Wu J; Wang C; Fang J; Stewart E; Harstead EH; E S; Robinson GW; Evans WE; Pappo A; Zuo J; Relling MV; Onar-Thomas A; Gajjar A; Stewart CF
    Clin Pharmacol Ther; 2013 Aug; 94(2):252-9. PubMed ID: 23820299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
    Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
    Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
    Lee JW; Pussegoda K; Rassekh SR; Monzon JG; Liu G; Hwang S; Bhavsar AP; Pritchard S; Ross CJ; Amstutz U; Carleton BC;
    Ther Drug Monit; 2016 Aug; 38(4):423-31. PubMed ID: 26960170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.